4503 On Other Exchanges
Symbol
Exchange
4503 is not on other exchanges.

astellas pharma inc (4503) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports/exports pharmaceutical products worldwide. The company offers Prograf, an immunosuppressant for the prevention of rejection in organ transplants; Vesicare, a treatment for overactive bladder; Protopic, a treatment for atopic dermatitis in the topical immunomodulator class; Harnal, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, a COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment for hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, a 5-HT3 receptor antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, the company offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. It has collaboration agreements with The University of Texas MD Anderson Cancer Center; Potenza Therapeutics, Inc.; Kanyos Bio, Inc.; Chromocell Corporation; and Ocata Therapeutics, Inc. The company also has license agreement with Immunomic Therapeutics, Inc.; collaborative research agreement with the National Institute of Advanced Industrial Science and Technology; and collaborative development agreement with the Institute of Medical Science, the University of Tokyo. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

17,217 Employees
Last Reported Date: 06/20/16
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥216.0M
Chief Administrative Officer, Chief Complianc...
Total Annual Compensation: ¥108.0M
Compensation as of Fiscal Year 2016.

astellas pharma inc (4503) Key Developments

Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine in Kidney Transplant Patients

Vical Incorporated and Astellas Pharma Inc. announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus (CMV) vaccine, ASP0113, versus placebo in kidney transplant patients receiving an organ from a CMV-seropositive donor. Results from the study demonstrated that the trial did not meet its primary endpoint, which was the proportion of patients having CMV viremia defined as a plasma viral load of = 1000 IU/mL by central laboratory assay through one year after first injection of study drug. Additionally, the secondary endpoints of CMV-associated disease and CMV-specific antiviral therapy, which were evaluated by an independent, blinded Adjudication Committee, were similar in both treatment groups. The safety profiles were generally similar between treatment groups. However, local injection site reactions were more common in the ASP0113 treatment group. Further detailed data from the trial is expected to be disclosed at an upcoming scientific congress.

Courtagen Life Sciences Collaborates with Astellas Pharma for Mitochondrial Disorder Drug Development

Courtagen Life Sciences, Inc. announced a collaboration with Astellas Pharma Inc. Courtagen will utilize its molecular information platform to aid in the development of a predictive model to support early stage therapeutic development for mitochondrial disease.

Astellas Pharma, Inc. Presents at Mizuho Investment Conference - Tokyo, Sep-12-2016

Astellas Pharma, Inc. Presents at Mizuho Investment Conference - Tokyo, Sep-12-2016 . Venue: Prince Park Tower Hotel, 4-8-1, Shibakoen, Minato-ku, Tokyo 105-8563, Japan.

 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4503.
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 16.2x
Price/Sales 2.5x
Price/Book 2.9x
Price/Cash Flow 13.7x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.